Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Alexion Pharmaceuticals, a biopharmaceutical company that develops and delivers life-changing drug therapies for patients with serious and life-threatening medical conditions has taken over Taligen Therapeutics for $111m.
Subscribe to our email newsletter
Additional contingent payments would be earned upon reaching various clinical efficacy and product approval milestones in both the US and European Union for up to six products.
With this acquisition, Alexion Pharma has obtains pre-clinical compounds including treatments for patients with ophthalmic diseases such as age-related macular degeneration (AMD), as well as other novel antibody and protein regulators of the complement inflammatory pathways.
Alexion Pharma CEO Leonard Bell said Taligen’s talented scientists and impressive technology will enhance Alexion’s staff and research and development programs, substantially increasing their ability to develop therapies for patients with severe diseases.
"As product development opportunities continue to expand, we look forward to increasing the quality, speed, and throughput of our combined current and future development programs for the benefit of patients worldwide, "Bell said.